Researchers identify new genetic target for acute myeloid leukaemia
4th May 2021
Researchers from the Wellcome Sanger Institute have identified a new genetic target, which is linked with poor prognosis, for the potential treatment of acute myeloid leukaemia (AML) – a type of blood cancer.
The specific genetic mutation in the CUX1 gene is involved in the development of AML when combined with other mutations in mice and human cell lines, according to the researchers.
The study, published last week in
Nature Communications, suggests that targeting the loss-of-function mutation in the CUX1 gene may offer a ‘new therapy avenue’ for AML patients.
Potential Strategy for Acute Myeloid Leukemia Therapy Identified
May 3, 2021
The results from in vitro and in vivo studies suggest that targeting a pathway that is essential for the survival of certain types of acute myeloid leukemia (AML) could offer a new therapeutic strategy. The research, by scientists at the Wellcome Sanger Institute, found that a specific genetic mutation that is linked with poor prognosis in blood cancer is involved in the development of the disease when combined with other mutations in mice and in human cell lines.
Reported in
Nature Communications, the findings provide new insights into how the loss-of-function mutation in the CUX1 gene leads to the development and survival of AML. The results suggest that identifying a pathway that is essential for these cancer cells to continue growing could lead to new, targeted therapies for some patients.
Researchers find new genetic target for blood cancer treatment ANI | Updated: Apr 30, 2021 14:51 IST
Cambridge [England], April 30 (ANI): Researchers from the Wellcome Sanger Institute found that a specific genetic mutation, which is linked with poor prognosis in blood cancer, is involved in the development of the disease when combined with other mutations in mice and human cell lines.
The study was published today in the journal Nature Communications.
The study provides a greater understanding of how the loss-of-function mutation in the CUX1 gene leads to the development and survival of acute myeloid leukaemia. The findings suggest that targeting a pathway that is essential for these cancer cells to continue growing could lead to new targeted therapies for some patients.
E-Mail
Targeting a pathway that is essential for the survival of certain types of acute myeloid leukaemia could provide a new therapy avenue for patients, the latest research has found.
Researchers from the Wellcome Sanger Institute found that a specific genetic mutation, which is linked with poor prognosis in blood cancer, is involved in the development of the disease when combined with other mutations in mice and human cell lines.
The study, published today (30th April) in
Nature Communications, provides a greater understanding of how the loss-of-function mutation in the
CUX1 gene leads to the development and survival of acute myeloid leukaemia. The findings suggest that targeting a pathway that is essential for these cancer cells to continue growing could lead to new targeted therapies for some patients.